How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants?
暂无分享,去创建一个
Thanyada Rungrotmongkol | Supot Hannongbua | Nadtanet Nunthaboot | Maturos Malaisree | Pornthep Sompornpisut | Thanyarat Udommaneethanakit | Pathumwadee Intharathep | T. Rungrotmongkol | S. Hannongbua | Nadtanet Nunthaboot | M. Malaisree | Pathumwadee Intharathep | P. Sompornpisut | T. Udommaneethanakit
[1] M G Ford,et al. Binding constants of neuraminidase inhibitors: An investigation of the linear interaction energy method. , 1999, Journal of medicinal chemistry.
[2] Arieh Warshel,et al. A surface constrained all‐atom solvent model for effective simulations of polar solutions , 1989 .
[3] Supot Hannongbua,et al. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. , 2007, Biophysical journal.
[4] J. Aqvist,et al. A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.
[5] David J. Stevens,et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.
[6] T. Hansson,et al. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. , 1995, Protein engineering.
[7] E. De Clercq,et al. Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.
[8] Mark von Itzstein,et al. The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.
[9] Hideo Goto,et al. Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.
[10] J. McKimm-Breschkin,et al. Mechanisms of resistance of influenza virus to neuraminidase inhibitors , 2001 .
[11] Keiji Fukuda,et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.
[12] J. N. Varghese,et al. Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.
[13] Erik De Clercq,et al. Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.
[14] Vasiliy P. Mishin,et al. Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.
[15] D. Mendel,et al. Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.
[16] J. Oxford,et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.
[17] Jan H. Jensen,et al. Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.
[18] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[19] Yoshihiro Kawaoka,et al. oseltamivir: descriptive study , 2022 .
[20] Alan J. Hay,et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.
[21] Jie J. Zheng,et al. Computational studies of H5N1 influenza virus resistance to oseltamivir , 2009, Protein science : a publication of the Protein Society.
[22] J. Åqvist,et al. Q: a molecular dynamics program for free energy calculations and empirical valence bond simulations in biomolecular systems. , 1998, Journal of molecular graphics & modelling.
[23] Thanyada Rungrotmongkol,et al. Understanding of known drug‐target interactions in the catalytic pocket of neuraminidase subtype N1 , 2008, Proteins.
[24] B. Lina,et al. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[25] A. Moscona,et al. Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.
[26] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[27] John B. Shoven,et al. I , Edinburgh Medical and Surgical Journal.
[28] Yi Guan,et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.
[29] Thanyada Rungrotmongkol,et al. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation , 2009, Amino Acids.
[30] G. Boivin,et al. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. , 2008, Antiviral research.
[31] R. Webster,et al. Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo , 2007, Journal of Virology.